Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1487-1493

  Manns, Angela ^a,f   Miley, Wendell J ^b   Wilks, Rainford J ^e   Morgan, Owen St C ^e   Hanchard, Barrie ^e   Wharfe, Gilian ^e   Cranston, Beverly ^e   Maloney, Elizabeth ^a   Welles, Seth L ^d   Blattner, William A ^c   Waters, David ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF THE WEST INDIES   (Jamaica)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SPASTIC PARAPLEGIA; T CELL LEUKEMIA;

ADOLESCENT; ADULT; AGED; BLOOD TRANSFUSION; CARRIER STATE; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MALE; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; PROVIRUSES; VIRAL LOAD;

EID: 0032730418     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315088     Document Type: Article

References (36)

1. 1. La Grenade L, Manns A, Fletcher V, et al. Clinical, pathologic and immunologic features of human T-lymphotrophic virus type 1 associated infective dermatitis of children. Arch Dermatol 1998;134:439-44.
2. 2. Mochizuki M, Watanabe T, Yoshimura K, et al. Uveitis associated with human T-cell lymphotropic virus type 1. Am J Opthalmol 1992;114:123-9.
3. 3. Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-I in Sjogren's syndrome. Lancet 1994;344:1116-9.
4. 4. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400.
5. 5. Kaplan JE, Osame M, Kubota M, et al. The risk of development of HTLV-I associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096-101.
6. 6. Cleghorn FR, Manns A, Falk R, et al. Effect of HTLV-I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995;87:1009-14.
7. 7. Maloney EM, Cleghorn FR, Morgan O StC, et al. The incidence of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:167-70.
8. 8. Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type 1 carriers in Miyazaki, Japan. J Infect Dis 1996;173:584-91.
9. 9. Murphy EL, Wilks R, Morgan O StC, et al. Health effects of human T-lymphotropic virus type 1 (HTLV-I) in a Jamaican cohort. Int J Epidemiol 1996;25:1090-7.
10. 10. de Thé G, Kazanji M. An HTLV-I/II vaccine: from animal models to clinical trials? J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1): S191-8.
11. 11. Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:193-201.
12. 12. Kira J, Koyanagi Y, Yamada T, et al. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol 1991;29:194-201.
13. 13. Yamaguchi K, Seiki Y, Yoshida M, Nishimura II, Kawano F, Takatsuki K. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis to T cell malignancy. Blood 1984;63:1235-40.
14. 14. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992;51:886-91.
15. 15. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Statist Assoc 1937;32:675-701.
16. 16. Friedman M. A comparison of alternative tests of significance for the problem of m rankings. Ann Math Statist 1940;11:86-92.
17. 17. Page EB. Ordered hypotheses for multiple treatments: a significance test for linear ranks. J Am Statist Assoc 1963;58:216-30.
18. 18. Varmus HE. Form and function of retroviral proviruses. Science 1982;216: 812-20.
19. 19. Yoshida M, Osame M, Kawai H, et al. Increased replication of HTLV-I in HTLV-I associated myelopathy. Ann Neurol 1989;26:331-5.
20. 20. Murata N, Hakoda E, Machica II, et al. Prevention of human T cell lymphotropic virus type 1 infection in Japanese macaques by passive immunization. Leukemia 1996;10:1971-4.
21. 21. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-20.
22. 22. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990;322:383-8.
23. 23. Manns A, Cleghorn FR, Falk RT, et al. Role of HTLV-I in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago. Lancet 1993;342:1447-50.
24. 24. Hisada M, Okayama A, Shioiri S. Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers or human T-lymphotropic virus type I. Blood 1998;92:3557-61.
25. 25. Manns A, Murphy EL, Wilks RJ, et al. Early antibody profile during HTLV-I seroconversion (letter). Lancet 1991;337:181-2.
26. 26. Usuku K, Sonoda S, Osame M, et al. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Ann Neurol 1988; 23(Suppl):S143-S150.
27. 27. Jeffrey KJM, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I associated myelopathy. Proc Natl Acad Sci USA 1999;96:3848-53.
28. 28. Manns A, Hanchard B, Morgan O, et al. HLA class II alleles associated with HTLV-I infection and adult T-cell leukemia/lymphoma in a Black population. J Natl Cancer Inst 1998;90:617-22.
29. 29. Ibrahim F, Fiette L, Gessain A, Buisson N, de-Thé G. Infection of rats with human T-cell leukemia virus type-I: susceptibility of inbred strains, antibody response and provirus location. Int J Cancer 1994;58:446-51.
30. 30. Levin MC, Lehky TJ, Flerlage AN, et al. Immunologic analysis of a spinal cord biopsy specimen from a patient with human T-cell lymphotropic virus type I-associatal neurologic disease. N Engl J Med 1997;336: 839-45.
31. 31. Ijichi S, Osame M. Human T lymphotropic virus type I (HTLV-I) associated myelopathy/tropical spastic paraparesis (HAM/TSP): recent perspectives. Intern Med 1995;34:713-21.
32. 32. Renjifo B, Borrero I, Essex M. Tax mutation associated with tropical spastic paraparesis/human T-cell leukemia virus type 1-associated myelopathy [published erratum in J Virol 1995;69:3964]. J Virol 1995;69:2611-6.
33. 33. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLV-I associated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990;28:50-6.
34. 34. Kubota R, Umehara F, Izumo S, et al. HTLV-I proviral DNA amount correlates with infiltrating CD4 lymphocytes in the spinal cord from patients with HTLV-I associated myelopathy. J Neuroimmunol 1994;53:23-9.
35. 35. Tosswill JHC, Taylor GP, Clewley JP, Weber JN. Quantification of proviral DNA load in human T-cell leukaemia virus type I infections. J Virol Methods 1998;75:21-6.
36. 36. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998;4: 586-93.